This inventor holds 1 USPTO granted patent. Top assignee: Novartis Ag. Active years: 2017.
Company Filing History:
Years Active: 2017
Title: Ngai Ling Ma: Innovator in Tuberculosis Treatment
Introduction: Ngai Ling Ma, based in Victoria, Australia, is a notable inventor recognized for his contributions to the field of pharmaceuticals. With a focus on developing innovative solutions for infectious diseases, he has made significant strides in the treatment of tuberculosis.
Latest Patents: Ngai Ling Ma holds a patent for "Pyridone derivatives and uses thereof in the treatment of tuberculosis." This patent details a compound that is effective in treating diseases mediated by the inhibition of mycolic acid biosynthesis through the inhibition of the Enoyl Acyl Carrier Protein Reductase enzyme (InhA). This innovation represents a vital advancement in the pharmaceutical industry, offering potential therapeutic benefits for tuberculosis patients.
Career Highlights: Currently, Ngai Ling Ma is associated with Novartis AG, a leading global healthcare company. His work at Novartis encompasses research and development in innovative drugs targeted at challenging diseases, further emphasizing his commitment to improving global health outcomes.
Collaborations: Throughout his career, Ngai Ling Ma has collaborated with esteemed colleagues, including Ravinder Reddy Kondreddi and Stefan Peukert. These partnerships highlight the significance of teamwork in advancing scientific research and innovation, fostering an environment of knowledge sharing and creativity.
Conclusion: Ngai Ling Ma stands out as a key figure in the development of new treatments for tuberculosis. Through his patent for pyridone derivatives, he has made a substantial impact on the pharmaceutical landscape. His collaboration with other experts further enhances the potential for future advancements in medical therapies, solidifying his role as a leading inventor in the fight against infectious diseases.